Acrivon Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Acrivon Therapeutics, Inc. (ACRV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $4.33 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-05-13
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.33, a 41.33% decline year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $7.38, a 55.04% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.76, a 5.54% increase year-over-year.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.51.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $5.78, a 43.07% increase from fiscal 2024.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $4.04, a 33.99% decline from fiscal 2023.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $6.12, a 140.00% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $2.55.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-03-31 | $4.33 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $5.78 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $5.77 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $5.44 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $7.38 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $4.04 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $4.04 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $4.04 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $4.76 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $6.12 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $5.53 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $5.22 10-Q · filed 2023-08-11 | |||
| 2023-03-31 | $4.51 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $2.55 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |